Genfit SA
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France. Show More...
-
Website https://www.genfit.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 3.80 EUR
-
Last Updated 29-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share EUR -0.79 -0.75 -0.35 -0.63 -0.74 -0.69 -1.25 -1.79 -2.55 -1.76 -1.76 Dividends EUR Payout Ratio % * Shares Mil 12.0 13.0 15.0 20.0 23.0 25.0 27.0 31.0 31.0 37.0 37.0 Book Value Per Share * EUR 1.03 0.24 0.16 0.87 2.31 2.57 2.91 3.86 2.24 2.47 2.16 Free Cash Flow Per Share * EUR -0.54 -0.53 -0.52 -0.4 -0.65 -0.81 -0.75 -1.36 -1.87 -1.89 Return on Assets % -26.87 -32.03 -20.55 -47.99 -29.48 -22.02 -28.6 -25.51 -30.43 -24.16 -24.16 Financial Leverage (Average) 3.74 6.52 3.45 2.07 1.23 1.25 1.16 2.81 10.96 3.69 3.69 Return on Equity % -78.47 -150.74 -95.86 -120.92 -40.29 -27.23 -33.97 -47.45 -127.06 -124.08 -124.08 Return on Invested Capital % -60.17 -150.22 -32.08 -65.15 -34.45 -25.48 -32.17 -27.79 -30.01 -24.62 -24.62 Interest Coverage -19.04 -19.93 -31.42 -99.23 -180.7 -304.73 -40.85 -6.28 -4.75 -4.75 Current Ratio 1.67 1.31 2.99 8.07 7.75 9.22 10.46 5.56 6.66 6.66 Quick Ratio 1.19 1.21 2.85 7.96 7.68 9.15 10.4 5.5 6.61 6.61 Debt/Equity 1.11 0.39 0.07 0.08 0.04 1.54 7.95 2.13 2.13